chlorthalidone has been researched along with Apoplexy in 23 studies
Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Serum uric acid independently predicts cardiovascular events in older persons with isolated systolic hypertension." | 9.09 | Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). ( Applegate, WB; Di Bari, M; Franse, LV; Pahor, M; Shorr, RI; Somes, GW; Wan, JY, 2000) |
| "Stroke: common 'GG' homozygotes had higher risk on lisinopril versus amlodipine [hazard ratio (HR)=1." | 5.14 | Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. ( Arnett, DK; Boerwinkle, E; Davis, BR; Eckfeldt, JH; Ford, CE; Leiendecker-Foster, C; Lynch, AI, 2009) |
| "The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was a randomized, double-blind, active, controlled clinical trial conducted to determine whether newer antihypertensive agents, including doxazosin, an alpha-blocker, differ from chlorthalidone, a diuretic, with respect to coronary heart disease (CHD) and other cardiovascular disease (CVD) events in hypertensive patients at high risk of CHD." | 5.10 | Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( , 2003) |
| "Serum uric acid independently predicts cardiovascular events in older persons with isolated systolic hypertension." | 5.09 | Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). ( Applegate, WB; Di Bari, M; Franse, LV; Pahor, M; Shorr, RI; Somes, GW; Wan, JY, 2000) |
| "The aim of this study was to investigate whether there is a genotype-by-treatment interaction in patients experiencing stroke and treated with one of three antihypertensive drugs, that is chlorthalidone, amlodipine, or lisinopril." | 3.80 | Pharmacogenetic effects of 'candidate gene complexes' on stroke in the GenHAT study. ( Arnett, DK; Boerwinkle, E; Davis, BR; Eckfeldt, JH; Ford, CE; Irvin, MR; Sørensen, IF; Sørensen, P; Vazquez, AI, 2014) |
| "There is significant controversy around whether chlorthalidone (CTD) is superior to hydrochlorothiazide (HCTZ) in hypertension management." | 3.77 | Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. ( Bleske, BE; Dorsch, MP; Erickson, SR; Gillespie, BW; Weder, AB, 2011) |
| "Asymptomatic carotid stenosis is when this narrowing occurs in people without a history or symptoms of this disease." | 3.01 | Pharmacological interventions for asymptomatic carotid stenosis. ( Cassola, N; Clezar, CN; Flumignan, CD; Flumignan, RL; Nakano, LC; Trevisani, VF, 2023) |
| "Incident stroke was significantly decreased by treatment in the Systolic Hypertension in Elderly Program (SHEP) Trial, but the reduction in fatal events was not statistically significant." | 2.73 | Long-term fatal outcomes in subjects with stroke or transient ischemic attack: fourteen-year follow-up of the systolic hypertension in the elderly program. ( Davis, BR; Kostis, JB; Patel, AB; Pressel, SL; Shea, ML; Wilson, AC, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (56.52) | 29.6817 |
| 2010's | 8 (34.78) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Itoga, NK | 1 |
| Tawfik, DS | 1 |
| Montez-Rath, ME | 1 |
| Chang, TI | 1 |
| Clezar, CN | 1 |
| Flumignan, CD | 1 |
| Cassola, N | 1 |
| Nakano, LC | 1 |
| Trevisani, VF | 1 |
| Flumignan, RL | 1 |
| Haywood, LJ | 3 |
| Davis, BR | 9 |
| Piller, LB | 2 |
| Simpson, LM | 1 |
| Ghosh, A | 1 |
| Einhorn, PT | 1 |
| Ford, CE | 6 |
| Probstfield, JL | 4 |
| Soliman, EZ | 1 |
| Wright, JT | 3 |
| Oparil, S | 3 |
| Cushman, WC | 2 |
| Furberg, CD | 1 |
| Habib, GB | 2 |
| Margolis, K | 1 |
| Whelton, PK | 2 |
| Sørensen, IF | 1 |
| Vazquez, AI | 1 |
| Irvin, MR | 1 |
| Sørensen, P | 1 |
| Boerwinkle, E | 3 |
| Eckfeldt, JH | 3 |
| Arnett, DK | 3 |
| Yamal, JM | 1 |
| Alderman, MH | 1 |
| Calhoun, DA | 1 |
| Fendley, HF | 1 |
| Franklin, SS | 1 |
| Pressel, SL | 2 |
| Sastrasinh, S | 1 |
| Thomopoulos, C | 1 |
| Parati, G | 1 |
| Zanchetti, A | 1 |
| Bath, PM | 1 |
| Geeganage, CM | 1 |
| Gray, LJ | 1 |
| Lynch, AI | 2 |
| Leiendecker-Foster, C | 2 |
| Dorsch, MP | 1 |
| Gillespie, BW | 1 |
| Erickson, SR | 1 |
| Bleske, BE | 1 |
| Weder, AB | 1 |
| Zhang, X | 1 |
| Rahman, M | 1 |
| Cutler, JA | 1 |
| Barzilay, JI | 1 |
| Brown, CD | 1 |
| Colon, PJ | 1 |
| Fine, LJ | 1 |
| Grimm, RH | 1 |
| Gupta, AK | 1 |
| Baimbridge, C | 1 |
| Henriquez, MA | 1 |
| Ilamaythi, E | 1 |
| Preston, R | 1 |
| Scott, I | 1 |
| Stowasser, M | 1 |
| Düsing, R | 1 |
| Diener, HC | 1 |
| Rahn, KH | 1 |
| Kuwajima, I | 1 |
| Yusuf, S | 1 |
| Patel, AB | 1 |
| Kostis, JB | 1 |
| Wilson, AC | 1 |
| Shea, ML | 1 |
| Perry, HM | 1 |
| Price, TR | 1 |
| Applegate, WB | 2 |
| Fields, WS | 1 |
| Guralnik, JM | 1 |
| Kuller, L | 1 |
| Pressel, S | 1 |
| Stamler, J | 1 |
| Koval, PG | 1 |
| McDiarmid, T | 1 |
| Franse, LV | 1 |
| Pahor, M | 1 |
| Di Bari, M | 1 |
| Shorr, RI | 1 |
| Wan, JY | 1 |
| Somes, GW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| Pharmacological Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Anti-hypertensive Treatment[NCT00006294] | 37,939 participants (Actual) | Observational | 1999-09-30 | Completed | |||
| [NCT00000514] | Phase 3 | 0 participants | Interventional | 1984-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for chlorthalidone and Apoplexy
| Article | Year |
|---|---|
Pharmacological interventions for asymptomatic carotid stenosis.
Topics: Aspirin; Atherosclerosis; Atorvastatin; Carotid Stenosis; Chlorthalidone; Fluvastatin; Hemorrhage; H | 2023 |
Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2015 |
[Recent intervention studies with antihypertensive drugs and their influence on guidelines].
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Convert | 2003 |
[ALLHAT trial--antithesis to the overuse of vasodilating antihypertensive drugs].
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2004 |
11 trials available for chlorthalidone and Apoplexy
| Article | Year |
|---|---|
Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Atrial Fibrillation; Atrial Flutter; C | 2018 |
Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Chlorthalido | 2013 |
Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.
Topics: Age Factors; Aged; Amlodipine; Cause of Death; Chlorthalidone; Confidence Intervals; Dose-Response R | 2014 |
Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2009 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
Topics: Amlodipine; Antihypertensive Agents; Canada; Chlorthalidone; Chronic Disease; Coronary Disease; Doub | 2012 |
Are thiazide diuretics preferred as first-line therapy for hypertension? An appraisal of The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Benzothiadiazines; Blood Chemical Analysis; Chlorthalidone; Diuretics; Dose-Respon | 2003 |
Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chlorthalidone; Coronary Dise | 2003 |
Long-term fatal outcomes in subjects with stroke or transient ischemic attack: fourteen-year follow-up of the systolic hypertension in the elderly program.
Topics: Adult; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cause of Death; Chlorthalidone; F | 2008 |
Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP).
Topics: Aged; Antihypertensive Agents; Atenolol; Brain Ischemia; Cerebral Hemorrhage; Chlorthalidone; Double | 2000 |
Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Biomarkers; Cardiovascular Dis | 2000 |
8 other studies available for chlorthalidone and Apoplexy
| Article | Year |
|---|---|
Contributions of Systolic and Diastolic Blood Pressures to Cardiovascular Outcomes in the ALLHAT Study.
Topics: Aged; Amlodipine; Blood Pressure; Blood Pressure Determination; Cardiovascular Diseases; Chlorthalid | 2021 |
Pharmacogenetic effects of 'candidate gene complexes' on stroke in the GenHAT study.
Topics: Aged; Amlodipine; Chlorthalidone; Female; Genotype; Humans; Lisinopril; Male; Middle Aged; Pharmacog | 2014 |
Ordinal reanalysis of the SHEP trial.
Topics: Antihypertensive Agents; Chlorthalidone; Clinical Trials as Topic; Data Interpretation, Statistical; | 2008 |
Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis.
Topics: Adult; Angina Pectoris; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Cholesterol; Heart | 2011 |
[The new (old) knowledge in primary prevention of stroke. It depends on lowering of blood pressure].
Topics: Adrenergic alpha-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic | 2003 |
Preventing vascular events due to elevated blood pressure.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Comorbidity; Doxazosin; Drug Thera | 2006 |
How effective is doxazosin compared with chlorthalidone in the treatment of hypertension?
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Coronary Disease; Diuretics; | 2000 |